Publications by authors named "M Gardembas"

Claim this Profile
A
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maria Elena Maccari, Martin Wolkewitz, Charlotte Schwab, Tiziana Lorenzini, Jennifer W Leiding, Martine Gardembas

J Allergy Clin Immunol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.
Antoine Machet, Caroline Poudou, Cécile Tomowiak, Thomas Gastinne, Martine Gardembas

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Stéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Martine Gardembas

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Stéphanie Dulucq, Franck E Nicolini, Delphine Rea, Pascale Cony-Makhoul, Aude Charbonnier, Martine Gardembas

Haematologica· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas

Pharmaceutics· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis